General Enterprise Ventures, Inc. (GEVI)

Ligand Pharmaceuticals Revenue

General Enterprise Ventures had revenue of $969.38K in the quarter ending March 31, 2025, with 123.87% growth. This brings the company's revenue in the last twelve months to $1.34M, up 49.74% year-over-year. In the year 2024, General Enterprise Ventures had annual revenue of $808.37K with 55.26% growth.

• Revenue (ttm): 1.34M
• Revenue Growth: +49.74%
• P/S Ratio: 60.94
• Revenue / Employee: 168.09K
• Employees: 8
• Market Cap: 81.95M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	808.37K	287.73K	55.26%
Dec 31, 2023	520.65K	457.91K	729.95%
Dec 31, 2022	62.73K	23.81K	61.19%
Dec 31, 2021	38.92K	-	-
Dec 31, 2020	-	-	-